Skip to content
  • Media
  • Investors
  • Media
  • Investors
  • TAMP Therapy Platform
    • Our Science
    • RenovoCath®
  • Physicians
    • Evidence
    • Resources
  • Patients
    • The Procedure
    • FAQs
    • Patient Stories
    • Physician Locator
  • About Us
    • Overview & Leadership
    • Board of Directors
    • Advisory Boards
  • Contact
  • Media
  • Investors
  • TAMP Therapy Platform
    • Our Science
    • RenovoCath®
  • Physicians
    • Evidence
    • Resources
  • Patients
    • The Procedure
    • FAQs
    • Patient Stories
    • Physician Locator
  • About Us
    • Overview & Leadership
    • Board of Directors
    • Advisory Boards
  • Contact
  • Media
  • Investors

Day: May 9, 2026

What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer Presented at SIR 2026 Annual Scientific Meeting, April 2026

https://renovorx.com/wp-content/uploads/2026/05/SIR_2026_TAMP_PET-CT_Abstract_2.pdf

RenovoCath is FDA-cleared for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of LAPC in an ongoing clinical trial conducted under an IND.

Facebook-f X-twitter Linkedin-in Youtube

Menu

  • TAMP Therapy Platform
  • Our Science
  • RenovoCath®
  • Physicians
  • Evidence
  • Clinical Trials
  • Patients
  • The Procedure
  • FAQs
  • Patient Stories
  • Physician Locator
  • About
  • Leadership
  • Board of Directors
  • Advisory Boards
  • Contact
  • TAMP Therapy Platform
  • Our Science
  • RenovoCath®
  • Physicians
  • Evidence
  • Clinical Trials
  • Patients
  • The Procedure
  • FAQs
  • Patient Stories
  • Physician Locator
  • About
  • Leadership
  • Board of Directors
  • Advisory Boards
  • Contact
  • 2570 W. El Camino Real, Suite 640
    Mountain View, CA 94040
  • (650) 284-4433
  • info@renovorx.com
© 2026 RenovoRx®. All rights reserved.

Privacy Statement | Terms of Use